Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

Open in Screener

DYN

Dyne Therapeutics Inc

Mar 20 • 04:00PM ET

17.56

-0.24 -1.35 %

Healthcare • Biotechnology • USA • NASD

Peers: BIIB VRTX CRSP ALNY BMRN RARE NTLA SRPT EDIT BLUE

| Held by: VTI XBI IWM VB VXF VBR IBB IWN SCHA VTWO

Index	RUT	P/E	-	EPS (ttm)	-3.54	Insider Own	27.21%	Shs Outstand	164.95M	Perf Week	-2.01%
Market Cap	2.90B	Forward P/E	-	EPS next Y	-3.09	Insider Trans	-1.80%	Shs Float	120.12M	Perf Month	15.15%
Enterprise Value	1.96B	PEG	-	EPS next Q	-0.77	Inst Own	91.34%	Short Float	16.08%	Perf Quarter	-7.09%
Income	-446.21M	P/S	-	EPS this Y	8.96%	Inst Trans	10.26%	Short Ratio	9.04	Perf Half Y	26.15%
Sales	0.00M	P/B	2.98	EPS next Y	2.11%	ROA	-47.52%	Short Interest	19.32M	Perf YTD	-10.22%
Book/sh	5.89	P/C	2.61	EPS next 5Y	13.20%	ROE	-55.71%	52W High	25.00 -29.76%	Perf Year	43.23%
Cash/sh	6.73	P/FCF	-	EPS past 3/5Y	-2.41% 3.39%	ROIC	-39.27%	52W Low	6.36 176.10%	Perf 3Y	45.61%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	5.77% 7.69%	Perf 5Y	11.07%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-5.72%	Oper. Margin	-	ATR (14)	1.26	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	22.25	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	51.73	Recom	1.31
Dividend Gr. 3/5Y	- -	Current Ratio	22.25	EPS Q/Q	13.34%	SMA20	3.66%	Beta	1.32	Target Price	38.19
Payout	-	Debt/Eq	0.17	Sales Q/Q	-	SMA50	3.05%	Rel Volume	2.37	Prev Close	17.80
Employees	258	LT Debt/Eq	0.17	Earnings	Mar 02 BMO	SMA200	13.69%	Avg Volume	2.14M	Price	17.56
IPO	Sep 17, 2020	Option/Short	Yes / Yes	EPS/Sales Surpr.	0.34% -	Trades		Volume	5,064,589	Change	-1.35%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-10-25	Upgrade	Oppenheimer	Perform → Outperform	$40
Oct-10-25	Downgrade	Oppenheimer	Outperform → Perform
Aug-25-25	Upgrade	Raymond James	Outperform → Strong Buy	$35
Jun-24-25	Initiated	Bernstein	Mkt Perform	$13
Jun-11-25	Resumed	Raymond James	Outperform	$37
Jun-02-25	Resumed	Oppenheimer	Outperform	$34
May-29-25	Initiated	Evercore ISI	Outperform	$46
Mar-12-25	Initiated	BMO Capital Markets	Outperform	$50
Mar-07-25	Initiated	Scotiabank	Sector Outperform	$50
Dec-13-24	Initiated	Robert W. Baird	Outperform	$46
Nov-26-24	Initiated	RBC Capital Mkts	Outperform	$45
Oct-24-24	Downgrade	JP Morgan	Overweight → Neutral	$43 → $35
May-21-24	Reiterated	Chardan Capital Markets	Buy	$31 → $42
Apr-30-24	Initiated	Morgan Stanley	Overweight	$40
Feb-20-24	Initiated	H.C. Wainwright	Buy	$36
Feb-27-23	Upgrade	Raymond James	Outperform → Strong Buy	$16 → $27
Feb-15-23	Initiated	Oppenheimer	Outperform	$34
Jan-26-23	Initiated	Guggenheim	Buy	$33
Jul-20-22	Initiated	Chardan Capital Markets	Buy	$17
Jul-12-22	Initiated	Raymond James	Outperform	$15

Show Previous Ratings

Mar-10-26 09:47PM	Dyne Therapeutics (DYN) Climbs 11.8% on Triple-Digit Price Target Upgrade (Insider Monkey) +11.81%
Mar-08-26 06:01PM	Dyne Therapeutics Announces Initiation of Phase 3 HARMONIA Trial of Z-Basivarsen in Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire)
06:00PM	Dyne Therapeutics Announces New Positive Cardiopulmonary Results from DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Mar-02-26 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-26-26 05:52AM	Sarepta CEO To Jump Ship After 'Tumultuous' Year (Benzinga)
07:30AM	Loading…
Feb-25-26 07:30AM	Dyne Therapeutics to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-22-26 04:00PM	Dyne Therapeutics Announces Upcoming Presentations Across Neuromuscular Pipeline at 2026 MDA Clinical & Scientific Conference (GlobeNewswire)
Feb-18-26 07:38PM	Bullish Analyst Opinion on Dyne (DYNE) Follows Rare Disease Drug Progress in Japan (Insider Monkey)
Feb-16-26 12:23PM	Dyne Therapeutics (DYN) Attains Orphan Drug Designation From Japanese Ministry (Insider Monkey)
Jan-27-26 09:16AM	Keros Therapeutics vs. Dyne: Which DMD Biotech Has More Upside? (Zacks)
Jan-20-26 07:30AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-15-26 11:35AM	Analysts Project 120% Upside To Dyne Therapeutics, Inc. (DYN) (Insider Monkey) -5.90%
Jan-12-26 12:00PM	Funding for Risky Biotechs Is Returning (The Wall Street Journal)
Jan-07-26 07:30AM	Dyne Therapeutics to Present at 44th Annual J.P. Morgan Healthcare Conference (GlobeNewswire) +7.01%
Dec-23-25 07:30AM	Dyne Therapeutics Appoints Vikram Karnani to Board of Directors (GlobeNewswire)
06:50AM	Loading…
Dec-22-25 06:50AM	Why Analysts See a Huge Upside for Dyne Therapeutics (DYN) (Insider Monkey)
Dec-11-25 04:05PM	Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
07:44AM	Dyne Therapeutics Shares Rise After Announcing Positive Topline Results for z-rostudirsen in Phase 1/2 DMD Trial (Insider Monkey)
Dec-10-25 06:20PM	Why Dyne Therapeutics Stock Was a Big Winner on Wednesday (Motley Fool) +6.78%
09:40AM	Amazon initiated, GE Vernova upgraded: Wall Street's top analyst calls (The Fly)
Dec-09-25 09:42PM	Dyne Therapeutics Announces Pricing of Upsized $350.0 Million Public Offering of Common Stock (GlobeNewswire) -16.94%
06:42PM	Why Dyne Therapeutics Stock Tanked on Tuesday (Motley Fool)
04:54PM	Biggest Market Movers Today, Dec. 9: WRBY, DYN, & More (Motley Fool)
02:22PM	Dyne Therapeutics (DYN) Climbs 9.5% on Stellar Results for DMD Therapy Candidate (Insider Monkey)
01:34PM	Dyne to seek accelerated approval of DMD drug on Phase I/II data (Clinical Trials Arena)
Dec-08-25 04:02PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire) +9.47%
03:07PM	Why Dyne Therapeutics Stock Was Blasting Higher Today (Motley Fool)
06:30AM	Dyne Therapeutics Announces Positive Topline Results from Phase 1/2 DELIVER Trial of Z-Rostudirsen in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
05:32AM	Dyne to seek Duchenne drug approval; Kymera, Wave and Structure shares soar (BioPharma Dive)
Dec-07-25 11:00AM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET (GlobeNewswire)
12:26AM	Loading…
Nov-30-25 12:26AM	Bernstein Sees Favorable Risk-Reward for Dyne Therapeutics (DYN) Ahead of Major DYN-251 Data Release (Insider Monkey)
Nov-21-25 03:43PM	Why Dyne Therapeutics Stock Was Crushing it This Week (Motley Fool) +5.27%
Nov-05-25 04:10PM	Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -12.89%
Nov-03-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire) +6.78%
Oct-28-25 05:24AM	Dyne (DYN) Jumps 41% as Jefferies Bets Firm to Benefit from Novartis-Avidity Merger (Insider Monkey)
Oct-27-25 06:17PM	Why Dyne Therapeutics Stock Crushed the Market on Monday (Motley Fool) +41.18%
04:54PM	This biotech's stock soared as investors look for the next buyout target (MarketWatch)
12:07PM	Why Avidity Biosciences And Dyne Therapeutics Stocks Soared 40% Monday (Investopedia)
05:26AM	Dyne, Avidity stocks soar as Novartis strikes $12 bln biotech deal (Investing.com)
04:39AM	Jefferies sees Dyne as key beneficiary of Novartis Avidity buyout (Investing.com)
Oct-16-25 04:33PM	Dyne's Zeleciment Basivarsen Shows Sustained Gains in DM1 Trial at One Year (Insider Monkey)
Oct-06-25 06:01PM	Dyne Therapeutics Announces Additional One-Year Clinical Data Demonstrating Functional Improvement from Phase 1/2 ACHIEVE Trial of Zeleciment Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) (GlobeNewswire) +10.28%
Oct-04-25 04:54PM	Dyne's Investigational DMD Drug DYNE-251 Gets Japan Orphan Drug Status After Strong Trial Data (Insider Monkey)
Oct-02-25 04:05PM	Dyne Therapeutics Appoints Brian Posner to its Board of Directors (GlobeNewswire)
Sep-29-25 08:35AM	Dyne Therapeutics Receives Orphan Drug Designation in Japan for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire) -5.93%
Sep-10-25 12:20AM	Raymond James Increases PT on Dyne Therapeutics Stock from $31 to $35, Maintains Buy Rating (Insider Monkey)
Aug-27-25 07:30AM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Aug-20-25 12:13AM	Morgan Stanley Reiterates a Buy Rating on Dyne Therapeutics (DYN), Keeps the PT (Insider Monkey)
Aug-17-25 11:41PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for Duchenne Muscular Dystrophy Therapy (Insider Monkey)
Aug-06-25 12:00PM	Avidity Biosciences stock soars on Novartis takeover approach report (Investing.com) +10.70%
Aug-04-25 07:30AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-251 in Duchenne Muscular Dystrophy (DMD) (GlobeNewswire)
Jul-31-25 09:55AM	Does Dyne Therapeutics (DYN) Have the Potential to Rally 285.57% as Wall Street Analysts Expect? (Zacks)
Jul-28-25 04:10PM	Dyne Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) -6.43%
Jul-16-25 07:00AM	Satellos Appoints Dr. Wildon Farwell as Chief Medical Officer (Business Wire) +12.68%
Jul-11-25 11:27AM	RBC Capital Maintains a Buy Rating on Dyne Therapeutics (DYN) With a $25 PT (Insider Monkey)
Jul-02-25 04:01PM	Dyne Therapeutics Announces Closing of Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares (GlobeNewswire)
Jun-30-25 09:45PM	Dyne Therapeutics Announces Pricing of $200.0 Million Public Offering of Common Stock (GlobeNewswire) -8.82%
04:05PM	Dyne Therapeutics Announces Proposed Public Offering of Common Stock (GlobeNewswire)
04:01PM	Dyne Therapeutics Secures Up to $275 Million in Debt Financing from Hercules Capital (GlobeNewswire)
Jun-24-25 12:46PM	Dyne Therapeutics Receives FDA Breakthrough Therapy Designation for DM1 Drug DYNE-101 (Insider Monkey)
Jun-18-25 09:45AM	Dyne at attractive entry point following pullback, says Chardan (TipRanks)
Jun-17-25 07:00AM	Dyne Therapeutics Announces FDA Breakthrough Therapy Designation for DYNE-101 and Updated Plan for Accelerated Approval in DM1 Following Type C Meeting (GlobeNewswire) -21.42%
Jun-16-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Provide Update on DYNE-101 for Myotonic Dystrophy Type 1, Tomorrow Tuesday, June 17 at 8:00 a.m. ET (GlobeNewswire)
Jun-05-25 07:30AM	Dyne Therapeutics to Present New Preclinical Data in Facioscapulohumeral Muscular Dystrophy at the FSHD Society International Research Congress (GlobeNewswire)
May-08-25 07:30AM	Dyne Therapeutics Reports First Quarter 2025 Financial Results and Recent Business Highlights (GlobeNewswire) +20.16%
Apr-25-25 05:05AM	EC grants orphan drug designation to Dyne Therapeutics DMD therapy (Pharmaceutical Technology)
Apr-24-25 07:30AM	Dyne Therapeutics Receives European Medicines Agency (EMA) Orphan Drug Designation for DYNE-251 in Duchenne Muscular Dystrophy (GlobeNewswire)
Apr-21-25 04:09PM	Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost (Investor's Business Daily) +14.20% +6.22%
Apr-15-25 07:30AM	Dyne Therapeutics Announces Chief Business Officer and Chief Scientific Officer Appointments (GlobeNewswire) +5.09%
Apr-14-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.11%
Apr-01-25 11:50AM	Biotech stocks slide as Marks resignation seen being negative for sector (TipRanks) -11.76%
Mar-30-25 03:50AM	abrdn Life Sciences Investors Q4 2024 Commentary (Seeking Alpha)
Mar-28-25 09:00AM	RNA Biotechs: Current State And Outlook (Seeking Alpha)
Mar-20-25 04:30PM	Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) to Newly Appointed Chief Financial Officer (GlobeNewswire)
04:19PM	Dyne Therapeutics appoints Erick Lucera as CFO (SeekingAlpha)
04:10PM	Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer (GlobeNewswire)
Mar-16-25 07:00PM	Dyne Therapeutics Announces New Long-Term Clinical Data from Phase 1/2 DELIVER Trial of DYNE-251 in Duchenne Muscular Dystrophy Demonstrating Unprecedented and Sustained Functional Improvement Through 18 Months (GlobeNewswire)
Mar-12-25 03:05PM	Dyne Therapeutics' $4.3 Billion Peak Sales Potential? Analyst Highlights Key Strengths And Risks (Benzinga)
01:12PM	BMO Capital Initiates Coverage on Dyne Therapeutics With Outperform Rating (GuruFocus.com)
Mar-11-25 07:30AM	Dyne Therapeutics to Present at Stifel 2025 Virtual CNS Forum (GlobeNewswire)
Feb-27-25 07:30AM	Dyne Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights (GlobeNewswire)
Feb-14-25 04:05PM	Dyne Therapeutics Announces Upcoming Presentations at the 2025 MDA Clinical & Scientific Conference (GlobeNewswire)
Feb-13-25 09:35AM	After Plunging -10.43% in 4 Weeks, Here's Why the Trend Might Reverse for Dyne Therapeutics (DYN) (Zacks)
Feb-06-25 09:39AM	Dyne Therapeutics, Inc. (DYN): Among the Best Rebound Stocks to Invest In Now (Insider Monkey) +6.89%
Feb-03-25 07:30AM	Dyne Therapeutics to Present at Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-28-25 09:35AM	Down -42.2% in 4 Weeks, Here's Why Dyne Therapeutics (DYN) Looks Ripe for a Turnaround (Zacks)
Jan-21-25 07:30AM	Dyne Therapeutics Receives FDA Fast Track Designation for DYNE-101 for the Treatment of Myotonic Dystrophy Type 1 (GlobeNewswire)
Jan-10-25 06:30AM	Dyne Therapeutics Reports New Clinical Data Showing Compelling Impact on Multiple Measures of Myotonic Dystrophy Type 1 (DM1); Dyne Plans to Initiate Registrational Expansion Cohort to Support Potential Submission for U.S. Accelerated Approval for DYNE-101 in DM1 in H1 2026 (GlobeNewswire) -31.15%
Jan-09-25 07:30AM	Dyne Therapeutics to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire)
Jan-08-25 04:05PM	Dyne Therapeutics to Host Investor Conference Call and Webcast to Review New Clinical Data from the ACHIEVE Trial Friday, January 10 at 8:00 a.m. ET (GlobeNewswire) -31.15%
Nov-22-24 06:43AM	Dyne Therapeutics Inc. (DYN): Among the NASDAQ Stocks with Biggest Upside Potential According to Analysts (Insider Monkey)
Nov-12-24 07:30AM	Dyne Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-07-24 04:15PM	Dyne Therapeutics to Present at Upcoming Investor Conferences (GlobeNewswire)
Oct-09-24 07:30AM	Dyne Therapeutics Presents Data at World Muscle Society Congress Highlighting Promise of FORCE Platform to Address Underlying Causes of Neuromuscular Diseases (GlobeNewswire)
Oct-07-24 05:32PM	Dyne Therapeutics, Inc. (DYN): A Hot Stock to Buy Now (Insider Monkey)
Sep-23-24 08:56AM	Dyne Therapeutics to Present at Chardan's 8th Annual Genetic Medicines Conference (GlobeNewswire) -5.36%
Sep-04-24 09:10AM	Dyne Called Its Sarepta-Rivaling Results 'Unprecedented,' But Shares Dive On C-Suite Changes (Investor's Business Daily) +5.70%
08:15AM	High-dose Spinraza meets study goal; Top Dyne executives exit (BioPharma Dive)
Sep-03-24 12:37PM	Muscle Disease Drug Developer Dyne Therapeutics Stock Plunges After Updated Data From Duchenne Muscular Dystrophy (Benzinga) -30.70%
06:31AM	Dyne Therapeutics Announces Key Leadership Appointments (GlobeNewswire)

Dyne Therapeutics, Inc. is a clinical-stage company, which engages in developing innovative life-transforming therapies for genetically driven muscle diseases. It develops a broad portfolio of therapeutics for muscle diseases, including lead programs in myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral muscular dystrophy. The company was founded by Jason P. Rhodes and Romesh R. Subramanian on December 1, 2017 and is headquartered in Waltham, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Posner Brian S	Director	Mar 11 '26	Buy	19.35	2,000	38,700	13,500	Mar 13 04:46 PM
Kersten Dirk	Director	Mar 11 '26	Sale	19.52	129,672	2,530,562	4,644,386	Mar 13 04:35 PM
Kersten Dirk	Director	Mar 10 '26	Sale	19.57	511,098	10,000,327	4,774,058	Mar 11 05:27 PM
Kersten Dirk	Director	Mar 09 '26	Sale	17.72	177,690	3,148,987	5,285,156	Mar 11 05:27 PM
ForDyne B.V.	Affiliate	Mar 11 '26	Proposed Sale	19.75	807,295	15,944,076		Mar 11 04:05 PM
Posner Brian S	Director	Mar 06 '26	Buy	15.06	3,000	45,180	11,500	Mar 10 05:33 PM
ForDyne B.V.	Affiliate	Mar 09 '26	Proposed Sale	17.72	807,295	14,306,720		Mar 09 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Mar 05 '26	Sale	14.90	148	2,205	154,581	Mar 06 04:10 PM
Kerr Douglas	Chief Medical Officer	Mar 05 '26	Sale	14.90	904	13,470	171,606	Mar 06 04:09 PM
Cox John	CEO & President	Mar 05 '26	Sale	14.90	2,732	40,707	374,145	Mar 06 04:08 PM
Cox John	Officer	Mar 05 '26	Proposed Sale	14.90	2,732	40,707		Mar 05 04:06 PM
Kerr Douglas	Officer	Dec 05 '25	Proposed Sale	20.72	880	18,231		Dec 05 04:56 PM
Cox John	Officer	Dec 05 '25	Proposed Sale	20.72	2,662	55,150		Dec 05 04:55 PM
Cox John	CEO & President	Dec 05 '25	Sale	20.72	2,662	55,157	196,877	Dec 05 04:11 PM
Kerr Douglas	Chief Medical Officer	Dec 05 '25	Sale	20.72	880	18,234	87,510	Dec 05 04:09 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Dec 05 '25	Sale	20.72	144	2,984	94,729	Dec 05 04:08 PM
Cox John	CEO & President	Sep 05 '25	Sale	13.41	2,640	35,402	199,539	Sep 09 04:31 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 04 '25	Sale	13.27	894	11,863	95,017	Sep 08 04:06 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Sep 05 '25	Sale	13.41	144	1,931	94,873	Sep 08 04:06 PM
Kerr Douglas	Chief Medical Officer	Sep 04 '25	Sale	13.27	3,552	47,135	89,263	Sep 08 04:03 PM
Kerr Douglas	Chief Medical Officer	Sep 05 '25	Sale	13.41	873	11,707	88,390	Sep 08 04:03 PM
Cox John	Officer	Sep 05 '25	Proposed Sale	13.41	2,640	35,404		Sep 05 04:14 PM
Kerr Douglas	Officer	Sep 04 '25	Proposed Sale	13.27	4,552	60,402		Sep 04 04:45 PM
Cox John	CEO & President	Jul 14 '25	Buy	9.11	100,000	911,000	242,179	Jul 15 05:11 PM
Scalzo Richard William	Officer	Jun 11 '25	Proposed Sale	14.75	1,330	19,619		Jun 11 04:30 PM
Beskrovnaya Oxana	Officer	Jun 11 '25	Proposed Sale	14.75	2,132	31,449		Jun 11 04:29 PM
Cox John	CEO & President	Jun 05 '25	Sale	13.35	4,060	54,201	142,179	Jun 06 04:07 PM
Kerr Douglas	Chief Medical Officer	Jun 05 '25	Sale	13.35	1,342	17,916	92,815	Jun 06 04:05 PM
Friedl-Naderer Johanna	Chief Commercial Officer	Jun 05 '25	Sale	13.35	146	1,949	95,911	Jun 06 04:03 PM
Kerr Douglas	Officer	Jun 05 '25	Proposed Sale	13.35	1,342	17,911		Jun 05 04:13 PM
Cox John	Officer	Jun 05 '25	Proposed Sale	13.35	4,060	54,186		Jun 05 04:11 PM
Scalzo Richard William	Officer	Jun 05 '25	Proposed Sale	13.35	914	12,198		Jun 05 04:09 PM
Beskrovnaya Oxana	Officer	Jun 05 '25	Proposed Sale	13.35	1,093	14,587		Jun 05 04:07 PM
Scalzo Richard William	Officer	May 16 '25	Proposed Sale	11.82	2,479	29,313		May 16 04:10 PM
Beskrovnaya Oxana	Officer	May 16 '25	Proposed Sale	11.82	2,589	30,614		May 16 04:09 PM

Open in Screener

ACGL

Arch Capital Group Ltd

Mar 20 • 04:00PM ET

92.30

+0.13 0.14 %

Financial • Insurance - Diversified • Bermuda • NASD

ACGL Arch Capital Group Ltd daily Stock Chart

Peers: CB AIG MKL WRB RNR PGR TRV CINF RLI

| Held by: VTI VOO VO IVV SPY VTV XLF VOE RSP FTCS

Index	S&P 500	P/E	7.94	EPS (ttm)	11.62	Insider Own	3.45%	Shs Outstand	359.00M	Perf Week	-1.25%
Market Cap	32.84B	Forward P/E	9.08	EPS next Y	10.16	Insider Trans	-2.38%	Shs Float	343.55M	Perf Month	-6.14%
Enterprise Value	-	PEG	2.76	EPS next Q	2.45	Inst Own	92.54%	Short Float	1.59%	Perf Quarter	-3.74%
Income	4.36B	P/S	1.69	EPS this Y	-4.70%	Inst Trans	-1.70%	Short Ratio	2.87	Perf Half Y	4.66%
Sales	19.43B	P/B	1.42	EPS next Y	8.06%	ROA	6.91%	Short Interest	5.46M	Perf YTD	-3.77%
Book/sh	65.11	P/C	-	EPS next 5Y	3.29%	ROE	19.54%	52W High	103.39 -10.73%	Perf Year	-0.16%
Cash/sh	-	P/FCF	5.36	EPS past 3/5Y	45.00% 28.39%	ROIC	16.09%	52W Low	82.44 11.95%	Perf 3Y	47.94%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	26.93% 18.36%	Gross Margin	-	Volatility	1.56% 1.83%	Perf 5Y	162.98%
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	3.38%	Oper. Margin	24.46%	ATR (14)	1.96	Perf 10Y	314.99%
Dividend Ex-Date	Nov 18, 2024	Quick Ratio	-	Sales Y/Y TTM	15.21%	Profit Margin	22.44%	RSI (14)	33.86	Recom	2.00
Dividend Gr. 3/5Y	- -	Current Ratio	0.47	EPS Q/Q	38.62%	SMA20	-4.40%	Beta	0.42	Target Price	108.80
Payout	0.00%	Debt/Eq	0.12	Sales Q/Q	8.49%	SMA50	-3.92%	Rel Volume	2.15	Prev Close	92.17
Employees	8000	LT Debt/Eq	0.12	Earnings	Feb 09 AMC	SMA200	0.22%	Avg Volume	1.91M	Price	92.30
IPO	Sep 14, 1995	Option/Short	Yes / Yes	EPS/Sales Surpr.	14.87% -13.00%	Trades		Volume	4,091,554	Change	0.14%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-16-25	Initiated	Mizuho	Neutral	$95
Nov-25-25	Resumed	RBC Capital Mkts	Outperform	$108
Oct-14-25	Initiated	Goldman	Sell	$88
Sep-16-25	Initiated	Wolfe Research	Peer Perform
Aug-13-25	Initiated	Citigroup	Buy	$113
Aug-13-25	Initiated	Cantor Fitzgerald	Neutral	$98
Jul-09-25	Downgrade	Keefe Bruyette	Outperform → Mkt Perform	$101
Jun-10-25	Downgrade	Jefferies	Buy → Hold	$100
Sep-05-24	Initiated	Barclays	Equal Weight	$120
Aug-23-24	Reiterated	ROTH MKM	Buy	$110 → $125
Jan-10-24	Initiated	TD Cowen	Outperform	$96
Dec-14-23	Initiated	Evercore ISI	In-line	$88
Nov-22-23	Initiated	Citigroup	Neutral	$91
Oct-05-23	Initiated	Deutsche Bank	Buy	$81
Sep-08-23	Initiated	Goldman	Neutral	$80
Jun-20-23	Initiated	Morgan Stanley	Overweight	$92
Jan-20-23	Initiated	BMO Capital Markets	Market Perform	$65
Jan-12-22	Reiterated	UBS	Buy	$49 → $52
Nov-19-21	Initiated	Jefferies	Buy	$50
Aug-17-21	Initiated	Wolfe Research	Outperform	$51

Show Previous Ratings

Mar-17-26 08:03AM	Arch Capital Group Ltd. to Report 2026 First Quarter Results on April 28 (Business Wire)
Mar-10-26 12:11PM	Arch Capital Group Stock: Is ACGL Outperforming the Financial Service Sector? (Barchart)
Mar-06-26 11:51AM	Can Heritage Insurance Retain its Beat Streak in Q4 Earnings? (Zacks)
Mar-05-26 08:30AM	Is the Options Market Predicting a Spike in Arch Capital Stock? (Zacks)
Mar-03-26 05:24AM	Arch Capital Group (ACGL) Delivers Record 2025 Operating Income and Robust ROE (Insider Monkey)
09:00AM	Loading…
Feb-27-26 09:00AM	Arch Capital Group Ltd. (ACGL) is Attracting Investor Attention: Here is What You Should Know (Zacks)
Feb-24-26 08:49AM	EverQuote Tops Q4 Estimates on Solid Automotive, Home Insurance Growth (Zacks)
Feb-19-26 11:18AM	Radian Group Q4 Earnings Top Estimates, MI Business Remains Strong (Zacks)
Feb-18-26 09:29AM	AXS Outperforms Industry, Trades Near 52-Week High: Time to Hold? (Zacks)
Feb-12-26 11:24AM	FAF Q4 Earnings Top, Revenues Rise Y/Y on Strong Title Segment (Zacks)
11:01AM	Palomar Q4 Earnings & Revenues Beat Estimates, Premiums Rise Y/Y (Zacks)
08:51AM	Arch Capital Stock Outlook: Is Wall Street Bullish or Bearish? (Barchart)
Feb-11-26 01:26PM	AIG Q4 Earnings Beat Estimates, Up Y/Y on Solid Underwriting (Zacks)
Feb-10-26 04:03PM	Arch Capital Group Ltd (ACGL) Q4 2025 Earnings Call Highlights: Strong Income Growth and ... (GuruFocus.com)
03:49PM	Arch Capital Group Q4 Earnings Call Highlights (MarketBeat)
11:15AM	Loading…
11:15AM	Cincinnati Financial Q4 Earnings Beat Estimates on Underwriting Income (Zacks)
11:14AM	Arch Capital Tops Q4 Earnings Estimates on Solid Underwriting (Zacks)
Feb-09-26 06:30PM	Compared to Estimates, Arch Capital (ACGL) Q4 Earnings: A Look at Key Metrics (Zacks)
05:45PM	Arch Capital Group (ACGL) Surpasses Q4 Earnings and Revenue Estimates (Zacks)
04:58PM	Arch Capital: Q4 Earnings Snapshot (Associated Press Finance)
04:25PM	Arch Capital Group Ltd. Reports 2025 Fourth Quarter Results (Business Wire)
10:50AM	TRV Stock Near 52-Week High: A Signal for Investors to Hold Tight? (Zacks)
Feb-08-26 07:38AM	Dow 50,000 sets table for inflation data, delayed January jobs report: What to watch this week (Yahoo Finance)
04:22AM	Arch Capital (ACGL) Navigates Market Cycles with Strength, Offering Investors Long-Term Value (Insider Monkey)
Feb-05-26 08:30AM	Here's How Much a $1000 Investment in Arch Capital Group Made 10 Years Ago Would Be Worth Today (Zacks)
Feb-04-26 05:02PM	Madison Asset Initiates MSA Safety Position (Motley Fool)
12:34PM	Is a Beat in Store for Cincinnati Financial This Earnings Season? (Zacks)
10:03AM	Will Arch Capital's Beat Streak Continue This Earnings Season? (Zacks)
10:00AM	First American Financial (FAF) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:15AM	Gear Up for Arch Capital (ACGL) Q4 Earnings: Wall Street Estimates for Key Metrics (Zacks)
08:55AM	Loading…
08:55AM	Why Investors Need to Take Advantage of These 2 Finance Stocks Now (Zacks)
Feb-03-26 10:31AM	What's in the Cards for Cboe Global This Earnings Season? (Zacks)
Feb-02-26 10:00AM	Arch Capital Group (ACGL) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jan-29-26 06:00PM	Arch Capital Group (ACGL) Rises As Market Takes a Dip: Key Facts (Zacks)
09:35AM	What's in the Cards for Willis Towers This Earnings Season? (Zacks)
Jan-28-26 08:55AM	How to Boost Your Portfolio with Top Finance Stocks Set to Beat Earnings (Zacks)
Jan-26-26 10:50AM	Allstate Rides on Pricing Power & Protection Unit, But Risks Persist (Zacks)
09:25AM	AJG Gears Up to Report Q4 Earnings: Here's What to Expect (Zacks)
Jan-23-26 09:20AM	Will Brown & Brown's Beat Streak Continue This Earnings Season? (Zacks)
Jan-22-26 10:21AM	W.R. Berkley Gears Up to Report Q4 Earnings: Here's What to Expect (Zacks)
08:30AM	Arch Capital Group Ltd. Thanks John Vollaro for 24 Years of Service (Business Wire)
Jan-20-26 06:15PM	Why the Market Dipped But Arch Capital Group (ACGL) Gained Today (Zacks)
Jan-16-26 09:37AM	Travelers Gears Up to Report Q4 Earnings: Here's What to Expect (Zacks)
Jan-13-26 06:00PM	Arch Capital Group (ACGL) Suffers a Larger Drop Than the General Market: Key Insights (Zacks)
08:55AM	Why Investors Need to Take Advantage of These 2 Finance Stocks Now (Zacks)
08:13AM	Arch Capital's Q4 2025 Earnings: What to Expect (Barchart)
Jan-12-26 12:10PM	Why Arch Capital (ACGL) Could Beat Earnings Estimates Again (Zacks)
08:55AM	How to Find Strong Finance Stocks Slated for Positive Earnings Surprises (Zacks)
Jan-09-26 09:30AM	ACGL Outperforms Industry, Trades Near 52-Week High: Time to Hold? (Zacks)
Jan-08-26 04:11PM	Arch Capital Group Ltd. to Report 2025 Fourth Quarter Results on February 9 (Business Wire)
Jan-07-26 06:00PM	Arch Capital Group (ACGL) Rises As Market Takes a Dip: Key Facts (Zacks)
09:37AM	KNSL Lags Industry, Trades at Premium: How to Play the Stock (Zacks)
Jan-02-26 06:15PM	Arch Capital Group (ACGL) Stock Sinks As Market Gains: What You Should Know (Zacks)
Dec-26-25 08:48AM	Is the Options Market Predicting a Spike in Arch Capital Stock? (Zacks)
Dec-19-25 02:52PM	Roth Capital Cites Low Catastrophe Losses for Arch Capital (ACGL) Earnings Beat While Highlighting Growth Concerns (Insider Monkey)
Dec-18-25 08:30AM	If You Invested $1000 in Arch Capital Group a Decade Ago, This is How Much It'd Be Worth Now (Zacks)
Dec-09-25 11:39AM	Wall Street Has a Mixed Opinion on Arch Capital (ACGL), Here's Why (Insider Monkey)
Dec-04-25 02:15PM	Arch Capital Group Ltd. (ACGL): A Bull Case Theory (Insider Monkey)
07:34AM	Is Arch Capital Stock Underperforming the Dow? (Barchart)
Dec-02-25 09:52AM	AXS Near 52-Week High: Time to Add the Stock for Better Returns? (Zacks)
Dec-01-25 08:30AM	Here's How Much a $1000 Investment in Arch Capital Group Made 10 Years Ago Would Be Worth Today (Zacks)
Nov-27-25 09:40AM	Should Value Investors Buy Arch Capital Group (ACGL) Stock? (Zacks)
Nov-26-25 11:30AM	Why Is Arch Capital (ACGL) Up 10.5% Since Last Earnings Report? (Zacks)
Nov-25-25 04:02PM	Ackman Seeks to Sell New Fund With a Bonus: a Stake in His Firm (Barrons.com)
Nov-21-25 10:51AM	Arch Capital Trades Above 50-Day SMA: Time to Buy ACGL Stock? (Zacks)
Nov-18-25 08:49AM	KNSL Lags Industry, Trades at Premium: Time to Hold the Stock? (Zacks)
Nov-17-25 09:03AM	NMIH Stock Near 52-Week High, Trades at a Discount: Time to Hold? (Zacks)
Nov-14-25 08:30AM	Here's How Much You'd Have If You Invested $1000 in Arch Capital Group a Decade Ago (Zacks)
Nov-13-25 09:15AM	The Travelers Companies, Inc. (TRV) Hits Fresh High: Is There Still Room to Run? (Zacks)
07:17AM	Are Wall Street Analysts Predicting Arch Capital Stock Will Climb or Sink? (Barchart)
Nov-11-25 10:20AM	WRB Stock Near 52-Week High: A Signal for Investors to Hold Tight? (Zacks)
09:40AM	Are Investors Undervaluing Arch Capital Group (ACGL) Right Now? (Zacks)
Oct-30-25 03:14PM	Arch Capital Group Ltd (ACGL) Q3 2025 Earnings Call Highlights: Record Profits and Strategic ... (GuruFocus.com)
12:07PM	Here's How BHRG Fuels Berkshire's Insurance and Investment Power (Zacks)
01:30AM	Arch Global Services India Opens New Office in Trivandrum to Drive Innovation (Business Wire)
Oct-28-25 01:29PM	Arch Capital Q3 Earnings Beat, Revenues Miss Estimates (Zacks)
01:30AM	Arch Global Services India Opens Technology Hub in Hyderabad to Accelerate Innovation (Business Wire)
Oct-27-25 06:00PM	Arch Capital (ACGL) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates (Zacks)
05:20PM	Arch Capital Group (ACGL) Q3 Earnings Beat Estimates (Zacks)
04:21PM	Arch Capital: Q3 Earnings Snapshot (Associated Press Finance)
04:05PM	Arch Capital Group Ltd. Reports 2025 Third Quarter Results (Business Wire)
09:19AM	Arch Capital Group Ltd (ACGL) Q3 2025 Earnings Report Preview: What To Expect (GuruFocus.com)
Oct-24-25 09:16AM	Arch Capital Group Ltd (ACGL) Q3 2025 Earnings Report Preview: What To Look For (GuruFocus.com)
Oct-23-25 10:47AM	Is a Beat in the Cards for Principal Financial This Earnings Season? (Zacks)
10:42AM	Will Brown & Brown Pull Off a Surprise This Earnings Season? (Zacks)
10:20AM	Can Arch Capital Sustain the Surprise Streak With Q3 Earnings Beat? (Zacks)
10:19AM	Can CINF Sustain its Surprise Streak With Q3 Earnings Beat? (Zacks)
Oct-22-25 10:00AM	Skyward Specialty Insurance (SKWD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release (Zacks)
09:15AM	What Analyst Projections for Key Metrics Reveal About Arch Capital (ACGL) Q3 Earnings (Zacks)
Oct-21-25 12:00PM	All You Need to Know About Arch Capital (ACGL) Rating Upgrade to Buy (Zacks)
09:40AM	Should Value Investors Buy Arch Capital Group (ACGL) Stock? (Zacks)
Oct-20-25 10:00AM	Arch Capital Group (ACGL) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
09:53AM	What's in the Cards for CME Group This Earnings Season? (Zacks)
08:50AM	Want Better Returns? Don't Ignore These 2 Finance Stocks Set to Beat Earnings (Zacks)
Oct-17-25 11:06AM	Nasdaq Gears Up to Report Q3 Earnings: Here's What to Expect (Zacks)
10:19AM	Will Chubb Limited Pull Off a Surprise This Earnings Season? (Zacks)
08:50AM	These 2 Finance Stocks Could Beat Earnings: Why They Should Be on Your Radar (Zacks)
Oct-15-25 06:00PM	Arch Capital Group (ACGL) Stock Sinks As Market Gains: What You Should Know (Zacks)
01:30PM	BRK.B vs. ACGL: Which Insurance Powerhouse Deserves the Spotlight? (Zacks)
09:45AM	Will W.R. Berkley Pull Off a Surprise This Earnings Season? (Zacks)

Arch Capital Group Ltd. engages in the provision of property and casualty insurance and reinsurance lines. It operates through the following segments: Insurance, Reinsurance, Mortgage, Corporate, and Other. The Insurance segment consists of insurance underwriting units which offer specialty product lines like construction and national accounts, excess and surplus casualty, lenders products, professional lines, and programs. The Reinsurance segment is composed of reinsurance underwriting which offers specialty product lines such as casualty, marine and aviation, other specialty, property catastrophe, property excluding property catastrophe, and other. The Mortgage segment includes U.S. and international mortgage insurance and reinsurance operations as well as GSE credit risk sharing transactions. The Corporate segment represents net investment income, other income, corporate expense, interest expense, net realized gains and losses, and net impairment losses. The Other segment refers to Watford Re. which is a variable interest entity. The company was founded by Clements Robert in March 1995 and is headquartered in Hamilton, Bermuda.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Posner Brian S	Director	Mar 11 '26	Sale	17.11	3,000	51,345	2,000	Mar 12 04:29 PM
Gansberg David	President, Arch Capital Group	Mar 10 '26	Option Exercise	18.90	10,770	203,553	342,466	Mar 12 04:29 PM
Gansberg David	President, Arch Capital Group	Mar 10 '26	Sale	96.37	5,907	569,266	336,559	Mar 12 04:29 PM
Papadopoulo Nicolas	CEO	Mar 10 '26	Option Exercise	18.90	21,930	414,477	893,524	Mar 12 04:29 PM
Papadopoulo Nicolas	CEO	Mar 10 '26	Sale	96.31	21,930	2,112,063	871,594	Mar 12 04:29 PM
Papadopoulo Nicolas	Officer	Mar 10 '26	Proposed Sale	96.31	21,930	2,112,063		Mar 10 04:23 PM
Gansberg David	Officer	Mar 10 '26	Proposed Sale	96.37	5,907	569,266		Mar 10 04:22 PM
Rajeh Maamoun	President, Arch Capital Group	Feb 11 '26	Option Exercise	27.12	47,430	1,286,086	481,019	Feb 13 04:31 PM
Rajeh Maamoun	President, Arch Capital Group	Feb 11 '26	Sale	96.12	47,430	4,558,858	433,589	Feb 13 04:31 PM
Rajeh Maamoun	Officer	Feb 11 '26	Proposed Sale	96.12	47,430	4,558,859		Feb 11 04:10 PM
PASQUESI JOHN M	CHAIR	Dec 12 '25	Sale	93.90	203,866	19,142,047	351,356	Dec 16 05:32 PM
PASQUESI JOHN M	CHAIR	Dec 15 '25	Sale	94.17	8,800	828,684	289,556	Dec 16 05:32 PM
PASQUESI JOHN M	Director	Dec 15 '25	Proposed Sale	94.17	8,800	828,683		Dec 15 04:53 PM
John Murray Pasquesi	Director	Dec 12 '25	Proposed Sale	93.81	28,866	2,707,802		Dec 12 05:11 PM
PASQUESI JOHN M	Director	Dec 12 '25	Proposed Sale	93.91	175,000	16,434,138		Dec 12 05:09 PM
Morin Francois	EVP AND CFO	Nov 28 '25	Sale	94.62	8,000	756,996	266,681	Dec 02 04:59 PM
Morin Francois	Officer	Nov 28 '25	Proposed Sale	94.62	8,000	756,996		Nov 28 01:48 PM
Rajeh Maamoun	PRESIDENT, ARCH CAPITAL GROUP	Aug 22 '25	Sale	94.15	10,000	941,464	433,589	Aug 25 07:08 PM
Rajeh Maamoun	Officer	Aug 22 '25	Proposed Sale	94.15	10,000	941,464		Aug 22 04:23 PM
Posner Brian S	Director	Aug 01 '25	Buy	17.34	1,000	17,338	5,000	Aug 04 04:23 PM
Morin Francois	EVP AND CFO	May 16 '25	Option Exercise	18.90	12,630	238,707	287,311	May 20 04:41 PM
Morin Francois	EVP AND CFO	May 16 '25	Sale	94.58	12,630	1,194,576	274,681	May 20 04:41 PM
Morin Francois	Officer	May 16 '25	Proposed Sale	94.58	12,630	1,194,575		May 16 05:16 PM
PASQUESI JOHN M	CHAIR	May 12 '25	Sale	94.01	75,060	7,056,060	579,218	May 14 05:50 PM
PASQUESI JOHN M	CHAIR	May 13 '25	Sale	94.72	23,996	2,272,940	555,222	May 14 05:50 PM
PASQUESI JOHN M	Director	May 13 '25	Proposed Sale	94.72	23,996	2,272,940		May 13 04:11 PM
John Murray Pasquesi	Director	May 12 '25	Proposed Sale	94.01	75,060	7,056,060		May 12 05:13 PM
PETRILLO LOUIS T	OFFICER OF SUBSIDIARY	May 09 '25	Option Exercise	18.90	16,650	314,685	156,673	May 12 05:09 PM
PETRILLO LOUIS T	OFFICER OF SUBSIDIARY	May 09 '25	Sale	94.53	16,650	1,573,944	140,023	May 12 05:09 PM
PETRILLO LOUIS T	Officer	May 09 '25	Proposed Sale	94.53	16,650	1,573,945		May 09 05:46 PM
Papadopoulo Nicolas	CEO	May 02 '25	Option Exercise	15.84	9,213	145,888	804,931	May 06 05:16 PM
Papadopoulo Nicolas	CEO	May 02 '25	Sale	92.48	7,636	706,177	795,718	May 06 05:16 PM

DYN

Dyne Therapeutics Inc

ACGL

Arch Capital Group Ltd

Upgrade your FINVIZ experience